DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Hegewisch-Becker S. et al.
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Lancet Oncol 2015;
16: 1355-1369
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.